These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36221415)

  • 21. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study.
    Negru S; Papadopoulou E; Apessos A; Stanculeanu DL; Ciuleanu E; Volovat C; Croitoru A; Kakolyris S; Aravantinos G; Ziras N; Athanasiadis E; Touroutoglou N; Pavlidis N; Kalofonos HP; Nasioulas G
    BMJ Open; 2014 May; 4(5):e004652. PubMed ID: 24859998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients.
    Yanus GA; Belyaeva AV; Ivantsov AO; Kuligina ESh; Suspitsin EN; Mitiushkina NV; Aleksakhina SN; Iyevleva AG; Zaitseva OA; Yatsuk OS; Gorodnova TV; Strelkova TN; Efremova SA; Lepenchuk AY; Ochir-Garyaev AN; Paneyah MB; Matsko DE; Togo AV; Imyanitov EN
    Med Oncol; 2013; 30(3):686. PubMed ID: 23943423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.
    Cohen SA; Turner EH; Beightol MB; Jacobson A; Gooley TA; Salipante SJ; Haraldsdottir S; Smith C; Scroggins S; Tait JF; Grady WM; Lin EH; Cohn DE; Goodfellow PJ; Arnold MW; de la Chapelle A; Pearlman R; Hampel H; Pritchard CC
    Gastroenterology; 2016 Sep; 151(3):440-447.e1. PubMed ID: 27302833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.
    Imamura Y; Lochhead P; Yamauchi M; Kuchiba A; Qian ZR; Liao X; Nishihara R; Jung S; Wu K; Nosho K; Wang YE; Peng S; Bass AJ; Haigis KM; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
    Mol Cancer; 2014 May; 13():135. PubMed ID: 24885062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of influencing factors of KRAS/NRAS/BRAF/PIK3CA gene mutation consistency in patients with advanced colorectal cancer].
    Jiang HQ; Wang BL; Guo W
    Zhonghua Yi Xue Za Zhi; 2021 Feb; 101(6):400-404. PubMed ID: 33611888
    [No Abstract]   [Full Text] [Related]  

  • 28. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
    Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
    Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
    Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
    Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation patterns and prognostic analysis of BRAF/KRAS/PIK3CA in colorectal cancer.
    Wang C; Pan D
    J Clin Lab Anal; 2022 Jun; 36(6):e24444. PubMed ID: 35435290
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Martianov AS; Mitiushkina NV; Ershova AN; Martynenko DE; Bubnov MG; Amankwah P; Yanus GA; Aleksakhina SN; Tiurin VI; Venina AR; Anuskina AA; Gorgul YA; Shestakova AD; Maidin MA; Belyaev AM; Baboshkina LS; Iyevleva AG; Imyanitov EN
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.
    Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ
    Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics.
    Voutsadakis IA
    Crit Rev Oncol Hematol; 2023 Jun; 186():103987. PubMed ID: 37059275
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Jin J; Shi Y; Zhang S; Yang S
    Acta Oncol; 2020 Jan; 59(1):66-74. PubMed ID: 31545109
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
    Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
    Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
    Haley L; Tseng LH; Zheng G; Dudley J; Anderson DA; Azad NS; Gocke CD; Eshleman JR; Lin MT
    Mod Pathol; 2015 Oct; 28(10):1390-9. PubMed ID: 26226847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients].
    Liu XN; Tian Z; Wei XF; Wang Q; Zhang JX; Jin MS; Duan XM
    Zhonghua Bing Li Xue Za Zhi; 2019 May; 48(5):373-377. PubMed ID: 31104677
    [No Abstract]   [Full Text] [Related]  

  • 39. PIK3CA Mutated Colorectal Cancers Without KRAS, NRAS and BRAF Mutations Possess Common and Potentially Targetable Mutations in Epigenetic Modifiers and DNA Damage Response Genes.
    Voutsadakis IA
    Cancer Genomics Proteomics; 2024; 21(5):533-548. PubMed ID: 39191495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer.
    Takahashi N; Yamada Y; Taniguchi H; Fukahori M; Sasaki Y; Shoji H; Honma Y; Iwasa S; Takashima A; Kato K; Hamaguchi T; Shimada Y
    BMC Res Notes; 2014 Apr; 7():271. PubMed ID: 24774510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.